Rapid Review Quiz: Continuous Glucose Monitoring Devices

Romesh Khardori, MD, PhD


May 31, 2023

According to a recent, multinational cohort study of more than 4500 people younger than 21 years with type 1 diabetes, youth with type 1 diabetes who used real-time CGM (rtCGM) and an insulin pump spent more time in target glucose range than those using intermittently scanned CGM (isCGM) and/or multiple daily insulin injections. The patients who used rtCGM and insulin pumps also spent less time above and below glucose targets and had fewer severe adverse events — either diabetic ketoacidosis or severe hypoglycemia — compared with isCGM without a pump.

The study included youth from the SWEET registry, a worldwide network of diabetes care centers for youth in 21 countries, between January 1, 2016, and December 31, 2021. Specific devices that were used in the trial were not listed, but patients were divided into four groups: 850 used isCGM with a pump; 1231 used isCGM without a pump; 2252 used rtCGM with a pump; and 886 used rtCGM without a pump.

After making relevant adjustments, the rtCGM–plus–insulin pump group were most likely to achieve the recommended greater than 70% time in target glycemic range at 36.2%, followed by rtCGM without pump at 20.9%, and then isCGM without pump at 12.5%. Patients using isCGM with an insulin pump were the least successful at meeting the target, at 11.3%.

The researchers observed similar trends for the recommended goal of under 4% time spent below range (< 70 mg/dL) and under 25% time spent above range (> 180 mg/dL); patients using rtCGM with a pump were most likely to achieve both of those goals, at 73.1% and 32.5%, respectively.

Learn more about blood glucose monitors.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.